Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...

If approved, lenacapavir would be the first and only twice-yearly HIV prevention choice for people who need or want PrEP.

Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...

Lenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears ...

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...

On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...

Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...

Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...

Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against ...